Université Paris Descartes

National Institute of Health and Medical Research

Assistance Publique-Hopitaux De Paris

Arterial Remodelling Technologies, Inc.

Scarcell Technologies

L'assistance Publique - Hopitaux De Paris

Centre National De La Recherche Scientifique

The Cleveland Clinic Foundation

Institut De Radioprotection Et De Surete Nucleaire

Université René Descartes (Paris V)

University of Montpellier I

The University Paris V, Faculte Necker

Universite Paris 5

Etat Francais—ministere De Al Defense—direction Centrale Du Service De Sante Des Armees

Etat Francais—ministere De La Defense—direction Centrale Du Service De Sante Des Armees

Antoine Lafont

Bernard Coulomb

Bruno Gogly

Michel R Vert

Patrick Sabaria

Mathieu Castela

Tahmer Sharkawi

Serge Piranda

Jean-Jacques Lataillade

Suming Li

Henri L Garreau

Serge Piranda Statice Sante

Fredrick Cornhill

Ayman Al Hajzen

Christine Linard

Michel Vert

Julie Sainz

Ayman Al Haj Zen

Frederick Cornhill

Summing Li

Michael R Vert

Compositions of matter, including cell populations and medicaments, are provided that are derived from equine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of equine cell therapies are provided.

Mammalian cell population and medicaments for cell therapies in equines and improved cell cultivation methods

Compositions of matter, including cell populations and medicaments, are provided that are derived from canine gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of canine cell therapies are provided.

Mammalian cell population and medicaments for cell therapies in canines and improved cell cultivation methods

Compositions of matter, including cell populations and medicaments, are provided that are derived from human gingival fibroblasts and have cell phenotypes that occur in proportions not found in natural gum tissue, but rather, are preferentially are selected to express proteins favoring angiogenesis and anti-inflammatory effects, while reducing cell populations that promote tumorigenicity and/or formation of metalloproteinases that inhibit tissue regeneration. Methods of generating such compositions are provided that increase proliferation many-fold compared to previously known methods, and methods of using such compositions in a wide range of human cell therapies are provided.

Mammalian cell population and medicaments for cell therapies in humans and improved cell cultivation methods

The present invention relates to a gingival fibroblast-derived product for use in the treatment or prevention of an immune-related disease in an individual.

Compositions useful for the treatment of immune-related diseases

The present invention relates to the use of gingival fibroblast-derived products to reduce hair loss and promote hair growth. Specifically, the invention relates to a product derived from gingival fibroblasts to be used in the treatment or prevention of alopecia, as well as in the promotion of natural hair growth and/or in the control of natural hair loss.

Use of gingival fibroblasts in the treatment of alopecia

The present invention relates to a device () for cell therapy, said device being designed to be applied on a living tissue and having at least a tight preferably biocompatible first wall (), designed to form a cavity () between said wall and said tissue, and further comprising means () to feed a healing substance in said cavity.

Device for administering cells and cell-therapy methods using said device

Methods for preparing a polymer-based stent assembly comprising an inflatable balloon catheter and a polymer-based stent resistant to relaxation-related negative recoil are provided. The methods comprise heating a polymeric cylindrical device which is at a final predetermined shape and diameter to a temperature sufficiently above the glass transition temperature (Tg) of the polymer and for a time sufficient to erase any memory of previous processing of the polymeric cylindrical device and then quenching the polymeric cylindrical device to provide an educated polymeric cylindrical device having a memory of the final predetermined diameter and shape, mounting the educated cylindrical device on an inflatable balloon catheter, reducing the diameter of the educated cylindrical device by heating to a temperature at or slightly above the Tg of the polymer while evenly applying pressure on the exterior surface of the wall of the cylindrical device, and then cooling the cylindrical device below the Tg of the polymer to provide a stent assembly comprising an inflatable balloon catheter and an expandable, educated, polymeric stent snugly and stably disposed thereon. Assemblies comprising an inflatable balloon and a polymer based stent that is substantially resistant to relaxation related recoil mounted snugly on the balloon are also provided.

Polymer-based stent assembly

The invention relates to the use of gingival fibroblasts for obtaining a cellular composition for treating arterial-remodelling pathology, for example an aneurysm, post-cryoplasty stenosis and restenosis, an aortic dissection or atherosclerosis.

Use of gingival fibroblasts for vascular cell therapy

The present invention relates to a method for treating a skin wound in an individual, comprising applying to the skin wound of the individual a therapeutically effective quantity of gingival fibroblasts.

Method for treating skin wounds

The present invention relates to a gingival fibroblast culture medium free of animal serum, comprising an animal cell culture medium, free of animal serum, to which is added:

Culture medium for gingival fibroblasts

The invention relates to the use of extracellular matrix regulators for producing a pharmacologically active covering on a platform or a prosthesis. This covering is of application to endoluminal prostheses, preferably using decorine or a fragment or derivative thereof as cellular matrix inhibitor.

Platforms, particularly prostheses, having biologically active coverings

Methods of crimping polymeric stents that simultaneously apply a radial force to the stent to reduce the diameter of the stent and a longitudinal force to elongate of the stent. According to one such method, a stent is inserted into an elastic tube having an inner surface that defines a passage. The tube is pulled to cause stretching of the tube. When the tube is stretched, the inner surface of the tube engages an outer surface of the stent and applies simultaneous longitudinal and radial forces to the outer surface of the stent. The simultaneously applied longitudinal and radial forces simultaneously reduce a radial extent of the stent and increase a longitudinal extent of the stent.

Stent crimping

The present invention provides a biodegradable polymeric stent having a programmed pattern of in vivo degradation. When deployed, the stent comprises a substantially cylindrical element having two open ends and a plurality of regions circumferentially spaced around the cylindrical element and extending from one open end to the other open end of the cylindrical element. Each of the regions is configured to have a desired in vivo lifetime. One region is designed to have a shorter in vivo lifetime than the other region or regions so that when the stent is deployed within the lumen of a vessel of a patient, the cylindrical element breaks apart from one open end of the cylindrical element to the other open end of the cylindrical element within a predetermined period of time after the stent is deployed in the patient. In one preferred embodiment the stent is a formed from a biodegradable polymeric band. The band includes a head having a slot and a tongue having a catch mechanism. The cylindrical element is formed by inserting a portion of the tongue through the slot to provide a cylindrical element having a first reduced diameter configuration. Following deployment, the cylindrical element is in a second expanded diameter configuration wherein the distal catch mechanism engages the inner surface of the head and prevents radial collapse or recoil of the polymeric stent. In a second preferred embodiment, the stent is formed from a plurality of interconnected polymeric bands.

Growing community of inventors

Paris, France

Antoine Lafont